Protein findings could open door to new class of antibiotics

In the face of growing resistance of bacteria to certain antibiotics, researchers at Oregon State University have made a breakthrough while studying peroxiredoxin.

Using X-ray crystallography, a technique that shows structures down to their atoms, researchers were studying what role peroxiredoxin could play in developing stronger antibiotics. Peroxiredoxin, which helps destroy hydrogen peroxide in healthy cells, reacts differently when placed in bacteria. There, peroxiredoxin provides a defense from our immune cells and increases the risk of the bacteria causing infections.  

While observing peroxiredoxin, researchers noticed that when it stops moving, it loses all function and causes cell death. This stoppage in mobility within bacterial cells means the bacteria loses immunity and is destroyed by the peroxiredoxin. Researchers were also able to uncover a special region of the bacterial peroxiredoxins that can be targeted to destroy the cells.

Researchers focused on developing a method to target specific damaging cells while leaving healthy cells untouched, which could potentially lead to the development of new antibiotics.

"There's a lot of potential for this to be foundational work, something we can build on to create a new class of antibiotics," said Arden Perkins, lead author, in collaboration with Andrew Karplus, a distinguished professor of biochemistry in the OSU College of Science. "The key concept is selectively restraining the motions of peroxiredoxins in some cells, inactivating its function and leading to the death of the cells you want to kill."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”